Listed by the USPTO as KIM, YUNSOO
Tech Center 1600 • Art Units: 1641 1644 1645 1674 1699
This examiner grants 66% of resolved cases
KIM, YUNSOO works in tech center 1600 and art unit 1641. The record contains 949 resolved cases, with an allowance rate of 66.0%. The median time to allowance is 1323 days, and interviews are associated with a 34.0% lift.
The portfolio lists Regeneron Pharmaceuticals Inc., Genentech Inc., and Akagera Medicines, Inc. The leading firms are COOLEY LLP, Jones Day, and GREENBERG TRAURIG, LLP (BOS). The interview measure supports evaluating examiner engagement as part of prosecution strategy. The recorded timing indicates that applicants should account for a substantial prosecution period when planning portfolio development, licensing, or other business milestones.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18011412 | TYPE 2 CYTOKINES AS PREDICTORS OF DISEASE SEVERITY AND/OR AS THERAPEUTIC TARGETS FOR COVID-19 | Non-Final OA | University of Virginia Patent Foundation |
| 18300339 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA AMYLOID ANTIBODIES | Non-Final OA | Biogen MA Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy66.0% of resolved applications examined by Yunsoo Kim were allowed (949 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +34.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Yunsoo Kim took 1,323 days on average from filing to allowance.
Yunsoo Kim examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
